SAB BIO Reveals Phase 1 Data on SAB-142 for Type 1 Diabetes

SAB BIO has announced additional Phase 1 data for its investigational drug, SAB-142, aimed at treating adult patients with established autoimmune Type 1 Diabetes (T1D). The results indicate early signals of C-peptide preservation, a critical marker in assessing the functionality of insulin-producing cells. This development could have significant implications for the management of T1D, which currently affects millions globally.

In a recorded webinar, Dr. Michael J. Haller, a key opinion leader in the field of diabetes, discussed the preliminary findings from the Phase 1 study. The data presented highlighted that patients receiving SAB-142 showed promising results in preserving C-peptide levels, suggesting potential benefits in maintaining insulin production.

Details from the Phase 1 Study

The Phase 1 data is now available on the SAB BIO corporate website in the Investors & Media section. The study focused on the measurement of C-peptide levels post-meal, which is critical in evaluating the residual insulin secretion in T1D patients. The findings, illustrated in a graph from the webinar, depict the mean area under the curve (AUC) for C-peptide levels, showcasing statistical significance in the treatment group compared to controls.

Dr. Haller referenced findings from a related study published in 2019 in the journal Diabetes, which demonstrated that low-dose anti-thymocyte globulin could preserve C-peptide levels and reduce HbA1c in new-onset Type 1 Diabetes patients. This earlier research laid the groundwork for understanding how immunomodulatory therapies can impact the disease course.

Implications for Type 1 Diabetes Management

The results of this Phase 1 study could mark a pivotal step in the treatment landscape for Type 1 Diabetes, a condition characterized by the autoimmune destruction of pancreatic beta cells. The ability to preserve C-peptide levels may help in managing blood glucose levels more effectively and reducing the risk of diabetes-related complications.

As patient populations continue to seek new therapeutic options, SAB BIO’s research into SAB-142 adds to the growing body of evidence supporting innovative treatment strategies. The company is committed to advancing its research and will continue to share updates as they progress through subsequent phases of clinical trials.

In conclusion, the recent data unveiled by SAB BIO and reviewed by Dr. Haller signals a promising advancement in the quest for effective treatments for Type 1 Diabetes. For more detailed information, interested parties can refer to the ongoing updates available through the company’s corporate communications.

For investor inquiries, please contact Cristi Barnett at [email protected] For media inquiries, reach out to Sheila Carlson at [email protected]